Native valve endocarditis due to Candida glabrata treated without valvular replacement: a potential role for caspofungin in the induction and maintenance treatment.

Published

Journal Article

Conventional antifungal therapy for fungal endocarditis has been associated with a poor cure rate. Therefore, combined medical and surgical therapy has been recommended. However, new potent antifungal agents, such as echinocandins, could increase the medical options and, in some cases, avoid the need for surgery. We report a case of Candida endocarditis treated successfully without valve replacement with intravenous liposomal amphotericin B (total dose, 4 g) and intravenous caspofungin (a 100-mg loading dose followed by 50 mg per day for 8 weeks) as induction therapy and intravenous caspofungin (100 mg 3 times per week for 12 weeks) as maintenance therapy.

Full Text

Duke Authors

Cited Authors

  • Jiménez-Expósito, MJ; Torres, G; Baraldés, A; Benito, N; Marco, F; Paré, JC; Moreno, A; Claramonte, X; Mestres, CA; Almela, M; García de la María, C; Pérez, N; Schell, WA; Corey, GR; Perfect, J; Jiménez de Anta, MT; Gatell, JM; Miró, JM

Published Date

  • October 1, 2004

Published In

Volume / Issue

  • 39 / 7

Start / End Page

  • e70 - e73

PubMed ID

  • 15472836

Pubmed Central ID

  • 15472836

Electronic International Standard Serial Number (EISSN)

  • 1537-6591

Digital Object Identifier (DOI)

  • 10.1086/424018

Language

  • eng

Conference Location

  • United States